Overview

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD

Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone mineral density.
Phase:
Phase 2
Details
Lead Sponsor:
Nastech Pharmaceutical Company, Inc.
Treatments:
Teriparatide